Spectral domain optical coherence tomography in a patient with adult-onset vitelliform dystrophy treated with intravitreal bevacizumab.
A patient with adult-onset vitelliform dystrophy received intravitreal injections of bevacizumab in one eye. During 4 months of follow-up, spectral domain optical coherence tomography (SD-OCT) showed a progressive decrease of yellowish deposits and complete resolution of subretinal fluid at the last followup. Despite the good anatomic outcome, the patient reported a mild decrease in visual acuity and persistent metamorphopsia. The clinical course and the correlation between the fundus findings and the morphologic information from SD-OCT data are described.
Lee
Joo Yong
JY
Department of Ophthalmology Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea.
Lim
Jongyoon
J
Chung
Hyewon
H
Kim
June-Gone
JG
Yoon
Young Hee
YH
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005583:Fourier Analysis; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab